Label‐Free Microfluidic Apheresis of Circulating Tumor Cell Clusters

Abstract

Screening liters of blood (i.e., apheresis) represents a generalized approach to promote the reliable access to circulating tumor cell clusters (CTCCs), which are known to be highly metastasis‐competent, yet ultrarare. However, no existing CTCC sorting technology has demonstrated high throughput, high yield, low shear stress, and minimal blood dilution simultaneously as required in apheresis. Here, a label‐free method is introduced termed Precision Apheresis for Non‐invasive Debulking of cell Aggregates (PANDA) to continuously isolate CTCCs from undiluted blood to clean buffer through size sorting, processing 1.4 billion cells per second. The cell focusing is optimized within whole blood leveraging secondary transverse flow and margination. The PANDA chip recovers >90% of spiked ≈24 rare HeLa cell clusters from 100 mL undiluted blood samples (equivalent to ≈500 billion blood cells) at 1 L h ⁻¹ throughput, with ≤20s device residence time, ≤15 Pa shear stress, and >99.9% return of blood components. The technology lays the groundwork for future routine isolation to increase the recovery of these ultrarare yet clinically significant tumor cell populations from large volumes of blood to advance cancer research, early detection, and treatment.

Abstract

A label‐free method is reported termed Precision Apheresis for Non‐invasive Debulking of cell Aggregates (PANDA) to continuously isolate circulating tumor cell clusters (CTCCs) from undiluted blood to clean buffer through size sorting at 1L h ⁻¹ throughput, processing 1.4 billion cells per second. The technology lays the groundwork to increase the recovery of CTCCs from large volumes of blood to advance cancer research, early detection, and treatment.